Version 1
: Received: 1 October 2023 / Approved: 2 October 2023 / Online: 2 October 2023 (03:22:52 CEST)
How to cite:
Hamo-Giladi, D.B.; Fokra, A.; Sabo, E.; KABALA, A.; Minkov, I.; Hadad, S.; Abassi, Z.; Khamaysi, I. Involvement of Heparanase in the Pathogenesis of Acute Pancreatitis: Implication of Novel Therapeutic Approaches. Preprints2023, 2023100026. https://doi.org/10.20944/preprints202310.0026.v1
Hamo-Giladi, D.B.; Fokra, A.; Sabo, E.; KABALA, A.; Minkov, I.; Hadad, S.; Abassi, Z.; Khamaysi, I. Involvement of Heparanase in the Pathogenesis of Acute Pancreatitis: Implication of Novel Therapeutic Approaches. Preprints 2023, 2023100026. https://doi.org/10.20944/preprints202310.0026.v1
Hamo-Giladi, D.B.; Fokra, A.; Sabo, E.; KABALA, A.; Minkov, I.; Hadad, S.; Abassi, Z.; Khamaysi, I. Involvement of Heparanase in the Pathogenesis of Acute Pancreatitis: Implication of Novel Therapeutic Approaches. Preprints2023, 2023100026. https://doi.org/10.20944/preprints202310.0026.v1
APA Style
Hamo-Giladi, D.B., Fokra, A., Sabo, E., KABALA, A., Minkov, I., Hadad, S., Abassi, Z., & Khamaysi, I. (2023). Involvement of Heparanase in the Pathogenesis of Acute Pancreatitis: Implication of Novel Therapeutic Approaches. Preprints. https://doi.org/10.20944/preprints202310.0026.v1
Chicago/Turabian Style
Hamo-Giladi, D.B., Zaid Abassi and Iyad Khamaysi. 2023 "Involvement of Heparanase in the Pathogenesis of Acute Pancreatitis: Implication of Novel Therapeutic Approaches" Preprints. https://doi.org/10.20944/preprints202310.0026.v1
Abstract
Abstract: Acute pancreatitis (AP) is a common gastrointestinal disease with high morbidity and mortality rate. Unfortunately, neither the etiology nor the pathophysiology of AP are fully un-derstood and causal treatment options are not available. Recently we demonstrated that Hepa-ranase (Hpa) is adversely involved in the pathogenesis of AP and inhibition of this enzyme ameliorates the manifestation of the disease. Moreover, a pioneer study demonstrated that As-pirin has inhibitory effect on Hpa. Another compound, which possesses a mild pan-creato-protective effect against AP, is Trehalose, a common disaccharide. We hypothesize that combination of Aspirin, Trehalose, PG545 (Pixatimod) and SST0001 (Roneparstat), specific inhib-itors of Hpa, may exert pancreato-protective effect better than each drug alone. Thus, the current study examines the pancreato-protective effects of Aspirin, Trehalose, PG545 and SST0001 in ex-perimental model of AP induced by Cerulein in wild-type (WT) and Hpa over-expressing (Hpa-Tg) mice. Cerulein-induced AP in WT mice was associated with significant rises in the se-rum levels of Lipase (X4) and amylase (X3) with enhancement of pancreatic edema index, inflammatory response, and autophagy. Responses to cerulein were all more profound in heparanase transgenic (Hpa-Tg) mice vs wild-type (WT) mice, evident by X7 and X5 folds increase in lipase and amylase levels, respectively. Treatment with Aspirin or Trehalose alone and even more so in combination with PG545 or SST0001 were highly effective, restoring the serum level of lipase back to the basal level. Importantly, a novel newly synthesized compound termed Aspirlose effectively ameliorated the pathogenesis of AP as a single agent. Collectively, the results strongly indicate that targeting Hpa by using anti-Hpa drug combinations constitute a novel therapy for this common orphan disease.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
